Teva Pharmaceutical Industries reported $1000M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Aspen Pharmacare ZAR 4.35B 1.28B Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Dr.Reddys Laboratories INR 26.92B 482M Dec/2025
Guangzhou Baiy CNY 2.22B 11.14M Mar/2026
Jiangsu Hengrui CNY 2.81B 191.05M Mar/2026
Kalbe Farma IDR 2.51T 410.17B Sep/2025
Richter Gedeon HUF 55.32B 3.03B Mar/2026
Sh Fosun Pharma CNY 3.27B 1.17B Mar/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026